Scienmag

OCTOBER 12, 2020

Credit: WEI Wei Exploration of new leukemia antigens and construction of appropriate delivery systems using FDA-approved material are important strategies for developing leukemia vaccines for clinic use.

Vaccination 93

Vaccination Vaccine Development Scientist 93

BioTech 365

SEPTEMBER 7, 2021

CSE: DTC FSE: DTC OTC: DTCFF PRESS RELEASE DEFENCE THERAPEUTICS DEVELOPMENT PROGRAM TO ENGINEER A NEW HPV VACCINE … Continue reading → . / Key word(s): Miscellaneous 07.09.2021 / 08:30 The issuer is solely responsible for the content of this announcement.

Engineer 40

Engineer Vaccination Vaccine Development 40

XTalks

FEBRUARY 21, 2024

This episode features an interview with Amir Reichman, CEO of Scinai Immunotherapeutics , a biopharma company focused on developing cutting-edge biological treatments within the inflammation and immunology (I&I) sector, with a primary focus on addressing autoimmune and infectious diseases.

Life Science 105

Life Science Development Antibody Vaccination 105

STAT News

NOVEMBER 15, 2022

As the Covid-19 pandemic spread across the world two years ago, one of India’s leading biotech companies was racing to develop a vaccine with crucial backing from the Indian government. Read the rest…

Vaccination 145

Vaccination Vaccine Engineer Clinical Trials 145

BioSpace

AUGUST 6, 2020

Novavax said the agreement will allow for the development and distribution of NVX?CoV2373, CoV2373, a recombinant vaccine engineered from the genetic sequence of SARS-CoV-2, in India and in low- and middle-income countries.

Vaccination 98

Vaccination Vaccine Development Engineer 98

BioPharma Reporter

SEPTEMBER 14, 2023

Vaxess Technologies, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, has announced an additional $9 million in venture capital funding, with investors including RA Capital, The Engine, and GHIC, and Ulu Ventures.

Vaccination 64

Vaccination Vaccine Life Science Engineer 64

pharmaphorum

MARCH 2, 2021

The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. A combination of urgent need, unprecedented investments, and advances in genetic engineering has allowed what was once mere speculation to become not only our reality, but our future.

Genetics 52

Genetics Vaccination Vaccine Development 52

Drug Discovery World

FEBRUARY 14, 2024

Vaccination responses need to be rapid, efficacious and cost-effective if they are to outpace new viral threats emerging across the globe, says Jian He (Jason) , Chemistry, Manufacturing and Controls (CMC) Head, WuXi Vaccines. This would give more people much faster access to more effective vaccines.

Protein 59

Protein Vaccination Vaccine Manufacturing 59

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials.

Engineer 52

Engineer Genetics Clinical Research Research 52

Drug Discovery World

MARCH 21, 2023

In a step forward for genetic engineering and synthetic biology, US researchers have modified E coli bacteria to be immune to infection by all natural viruses tested so far. Genetic engineering The findings build on earlier efforts by genetic engineers, which involved genetically reprogramming E.

Engineer 52

Engineer Genetic Engineering Scientist Bacteria 52

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. Since 2004, the NIAID has been championing the discovery and development of the cytomegalovirus (CMV) vector used to deliver the HIV vaccine material to the immune system without causing disease.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Pharmaceutical Technology

JULY 6, 2022

The mRNA technology was used for the development of the Covid-19 vaccine. CureVac sought fair compensation for infringement of a portfolio of its intellectual property rights used to produce and sell BioNTech and Pfizer’s mRNA Covid-19 vaccine, Comirnaty.

Vaccination 182

Vaccination Vaccine Gene Therapy Engineer 182

Scienmag

JANUARY 4, 2021

In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus. Credit: UAB BIRMINGHAM, Ala.

Vaccination 98

Vaccination Vaccine Antibody Development 98

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer. Pfizer Inc. Jansen, Ph.D., who will be retiring from Pfizer.

Vaccination 40

Vaccination Vaccine Development Research 40

pharmaphorum

SEPTEMBER 10, 2020

Two UK biotechs – Destiny Pharma and Sporegen – have joined forces to develop a nasal spray that they say could serve as a first line of defense against coronavirus infections. The spray that will be developed alongside Destiny Pharma – called SPOR-COV – is a modified form of B. Image: Allonweiner at English Wikipedia.

Vaccination 133

Vaccination Vaccine Bacterium Antibody 133

Drug Discovery World

NOVEMBER 20, 2023

Raquel Sanches-Kuiper , Vice President of Science and Applications at Evonetix, and Clare Whitewoods , Marketing Communications Manager at Evonetix, look at the benefits synthetic DNA brings to pharmaceutical development. The Covid-19 pandemic demonstrated the potential for mRNA vaccines.

DNA 69

DNA Engineer Antibody Gene 69

Drug Discovery World

NOVEMBER 30, 2022

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial. . million to support further development of the re-engineered technology for use in the global response to future disease outbreaks. . Clamp technology . The University of Queensland. .

Vaccination 52

Vaccination Vaccine Immune Response Engineer 52

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Vaccines Taskforce and National Institute for Health Research played pivotal roles in the rapid recruitment and enrollment of volunteers.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

pharmaphorum

AUGUST 23, 2021

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

Pharmaceutical Technology

MAY 31, 2023

The company is also looking at developing therapies based on individual patient neoantigens in patient human leukocyte antigens (HLAs). Anocca’s platform features libraries of engineered human cells that allow for standardised analysis of T-cell biology, per the company’s website.

Gene Therapy 130

Gene Therapy Gene Engineer Vaccination 130

The Pharma Data

JULY 29, 2021

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines. HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. Takeda will retain commercialization rights in Japan and HilleVax will integrate certain Japan development activities into its global development.

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

Drug Discovery World

MAY 23, 2024

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The researchers will use a genetically engineered herpes simplex virus type 1 to eliminate cancer cells. million of funding for this research project.

Genetic Engineering 59

Genetic Engineering Engineer Immune Response Vaccination 59

Scienmag

JANUARY 6, 2021

Funding for device that gives vaccine and monitors response Credit: IMPACT, Swansea University Researchers at Swansea University have received £230,000 to develop the world’s first smart vaccine device that will both deliver the COVID-19 vaccine and measure its efficacy through monitoring the body’s associated response.

Vaccination 94

Vaccination Vaccine Research Development 94

pharmaphorum

JANUARY 5, 2023

The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio. Biotech Moderna, Inc.

Gene Sequencing 97

Gene Sequencing DNA Vaccination Vaccine 97

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society 1 state that “a little over 1.9

Development 64

Development Research Drugs Antibody 64

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 That analysis also showed that the Novavax COVID-19 vaccine was 96.4

Protein 97

Protein Vaccination Vaccine Trials 97

XTalks

NOVEMBER 23, 2020

Adding to recent announcements from Pfizer and Moderna on the efficacy of their COVID-19 vaccine candidates, AstraZeneca and Oxford revealed today that their vaccine contender is 70 percent effective, and could be as high as 90 percent. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

pharmaphorum

MARCH 30, 2022

CureVac and GlaxoSmithKline’s first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical trial last year, but they aren’t giving up. ” The post CureVac and GSK try again with COVID-19 vaccine appeared first on.

Vaccination 64

Vaccination Vaccine Protein Antibody 64

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. We have been very impressed by their vision and the relevance of their platform.”.

Genome 105

Genome Genomics Medicine Development 105

Pharmaceutical Technology

APRIL 20, 2023

Targovax has unveiled plans to rebrand as Circio , reflecting its strategic shift to focus on expediting the development of its innovative circular RNA (circRNA) platform. Circio aims to develop new circRNA medicines initially for cancer, then plans to expand rapidly into vaccines and gene therapy.

Gene Therapy 240

Gene Therapy RNA Gene Engineer 240

Drug Discovery World

JUNE 21, 2023

Hosted by DDW and sponsored by Elegen, “Where are the breakthroughs in mRNA drug discovery and development?” Join this free webinar to learn about the opportunities in mRNA drug discovery and development. What you will learn: What are the challenges in relation to the development of mRNA therapeutics and how can they be overcome?

Development 52

Development Drugs DNA Engineer 52

Pfizer

APRIL 26, 2023

But the underlying question is always the same: How will Pfizer and BioNTech ensure a seamless distribution of our vaccine? With the pandemic still raging, our vaccine will be in high demand and, upon authorization or approval, rapidly utilized to help beat back the virus. In the U.S.,

Vaccination 52

Vaccination Vaccine Manufacturing Containment 52

Pharmaceutical Technology

FEBRUARY 24, 2023

ACE-1334 is under clinical development by Merck and currently in Phase I for Lung Disease. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is developed based on protein engineering platform.

Production 100

Production Vaccination Vaccine Engineer 100

Pharmaceutical Technology

JUNE 1, 2023

Pneumagen has raised £8m ($10 million) for the further development of its intranasal antiviral drug neumifil in Phase II studies for chronic obstructive pulmonary disease (COPD) patients suffering from virus-induced exacerbations. Neumifil consists of an engineered carbohydrate-binding module domain of a Streptococcus pneumoniae protein.

In-Vitro 130

In-Vitro Engineer Protein Vaccination 130

Scienmag

MARCH 19, 2021

Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds. MIT researchers have now developed a vaccination strategy that can create an army of T cells that are […].

Vaccination 48

Vaccination Vaccine Immune Response Development 48

Drug Discovery World

NOVEMBER 27, 2023

Across the biotherapeutics workflow The landscape of large molecule drug development has evolved significantly in recent decades. Technological innovations supporting discovery and development stages have concentrated on both upstream and downstream aspects of the workflow. This article is sponsored by Revvity.

Production 59

Production Engineer Gene Editing Gene 59

The Pharma Data

APRIL 18, 2022

Takeda today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid ® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Trials 52